Large patient registries have become the quiet workhorses of modern dermatology. They feed the safety analyses that shape how biologic drugs are prescribed, they anchor the outcome measures used in clinical trials, and they supply the real-world evidence that regulators increasingly demand before approving new therapies for chronic skin disease. But a registry is only as good as the population it captures, and a new research letter published in the Archives of Dermatological Research raises a deceptively simple question about one of the most prominent psoriasis registries in the United States: does the people inside the database actually look like the people walking into dermatology clinics?
The study, led by Joseph McGrath and Evelyn Fagan Burley, with senior authorship from Sarah Lonowski and Kaleb Michaud at the University of Nebraska Medical Center, set out to assess representation in the FORWARD registry, a nation-wide, patient-reported psoriasis and psoriatic arthritis registry. The team’s approach was deliberately grounded: rather than comparing FORWARD against census data or other registries, they compared it against the electronic medical record of a single academic institution, using that clinic population as a benchmark for the kinds of patients who seek care for psoriasis in a real-world setting. The work was approved under institutional review board protocol 0770-24-EP, and the authors report no funding and no conflicts of interest.
FORWARD is not a small or casual undertaking. Described in a 2024 paper in the Journal of Psoriasis and Psoriatic Arthritis, it is a novel registry built around patient-reported outcomes, collecting longitudinal data directly from people living with psoriasis and psoriatic arthritis across the country. Patient-reported outcome registries occupy an important niche in dermatology because many of the outcomes that matter most to patients, such as itch, fatigue, skin-related stigma, and functional impairment, are poorly captured by routine clinical documentation. By asking patients directly and repeatedly over time, FORWARD can track disease trajectories in a way that claims data or chart reviews cannot.
Yet the very design that gives such registries their power also introduces a structural vulnerability. Enrollment in FORWARD is voluntary and, like many contemporary registries, it relies heavily on digital infrastructure for recruitment and follow-up. A well-documented body of research, including a 2019 analysis in the Journal of the American Medical Informatics Association by Toscos and colleagues, has shown that technology-based research participation is not demographically neutral: patients who sign up for app-based or web-based studies tend to differ systematically from those who do not, in ways that track both socioeconomic status and health status. If those selection pressures operate within FORWARD, the registry’s findings could quietly drift away from the broader psoriasis population it is meant to represent.
This is the concern that motivated the single-institution comparison. Registry science in dermatology has wrestled with questions of validity for more than a decade. A 2017 commentary in the British Journal of Dermatology by Egeberg and Nast urged a critical eye on registry data in psoriasis, and a 2011 systematic review in BMC Medical Research Methodology by Langham and colleagues found that large prospective observational studies in psoriasis and psoriatic arthritis varied widely in quality and in how transparently they reported potential biases. A 2016 review of patient registries in dermatology by DiMarco, Hill, and Feldman in the Journal of the American Academy of Dermatology similarly catalogued the methodological trade-offs inherent in registry design. Against that backdrop, the Nebraska team’s audit is less an indictment than a routine but essential quality check, the epidemiological equivalent of calibrating an instrument before trusting its readings.
The logic of the comparison deserves unpacking, because it illustrates a core technique in registry validation. When researchers want to know whether a national registry is representative, they need an external reference population. Census data offer demographics but no clinical detail; claims databases offer clinical breadth but shallow phenotyping. A single academic institution’s electronic medical record, by contrast, provides a richly characterized cohort of diagnosed psoriasis patients with documented demographics, comorbidities, and treatment histories. By comparing the characteristics of FORWARD enrollees against eligible patients at the institution, the researchers could identify dimensions along which the registry over- or under-represents the clinical population, whether by age, sex, disease severity, psoriatic arthritis status, or treatment intensity.
Why does this matter so much for psoriasis specifically? Psoriasis is a chronic immune-mediated disease affecting roughly two to three percent of many adult populations, and its management has been transformed over the past two decades by biologics and targeted oral therapies. Decisions about which patients should escalate to expensive systemic therapy, how to weigh cardiovascular and metabolic comorbidity in treatment planning, and how to monitor long-term drug safety all draw heavily on observational evidence. If registry cohorts skew toward younger, more digitally connected, more engaged patients, then estimates of treatment effectiveness, adverse event rates, and comorbidity burden may not transfer cleanly to older patients, those with limited internet access, or those managed outside specialty centers. Generalizability, in other words, is not an abstract statistical virtue; it determines whose care is guided by the evidence.
The study also speaks to a broader and increasingly urgent conversation about equity in data-driven medicine. Registries feed algorithms, guidelines, and policy, and any systematic under-representation within them propagates silently into those downstream products. The authors’ decision to test representation using a concrete, verifiable comparator, rather than simply asserting generalizability, models a practice that other registry-based fields would do well to emulate. It also highlights the distinctive value of academic medical centers as audit points: their patient populations are themselves imperfect samples of the general population, but they are transparent, documentable samples, which makes them useful yardsticks even with their own known biases.
It is worth emphasizing what this research letter does not claim. A single-institution comparison cannot, by itself, establish how representative FORWARD is of the entire United States psoriasis population, and the authors present their work as an assessment rather than a definitive verdict. The data underlying the comparison were drawn from the institution’s electronic medical record under IRB oversight and were deliberately not made publicly available, in order to protect patient confidentiality, a constraint that reflects the tension between methodological transparency and privacy in clinical data research. The letter’s contribution lies in its method and its framing: it demonstrates that representation audits are feasible, inexpensive, and informative, and it invites similar checks at other institutions to build a fuller picture of where the registry aligns with clinical reality and where it diverges.
For clinicians and patients, the practical takeaway is one of informed confidence. FORWARD remains a vital resource, and the fact that its stewards, including Michaud, a veteran registry scientist best known for decades of work on rheumatology registries, subjected their own cohort to external scrutiny is a mark of methodological seriousness rather than weakness. The study, published as volume 318, article 423 of the Archives of Dermatological Research, arrives at a moment when real-world evidence is being asked to carry more weight than ever in dermatology. Ensuring that the patients inside the database resemble the patients in the exam room is the unglamorous, foundational work on which everything else, from drug safety signals to treatment guidelines, ultimately depends. As registries grow larger and more influential, expect more studies of this kind, quietly checking the mirror to make sure it reflects everyone it claims to.
Subject of Research: Evaluation of demographic and clinical representation in the FORWARD national psoriasis registry using a single-institution electronic medical record comparison
Article Title: Assessing representation in a nation-wide psoriasis registry: a single-institution comparison
Article References: McGrath, J., Burley, E. F., Sullivan, C., Kilton, M., Michaud, K., & Lonowski, S. (2026). Assessing representation in a nation-wide psoriasis registry: a single-institution comparison. Archives of Dermatological Research, 318(1), Article 423. https://doi.org/10.1007/s00403-026-04860-9
Image Credits: AI Generated
DOI: 10.1007/s00403-026-04860-9
Keywords: FORWARD registry, psoriasis, psoriatic arthritis, patient registries, representation, generalizability, selection bias, patient-reported outcomes, dermatology, electronic medical records, real-world evidence, registry methodology
News Source: Ophelia Keating. (October 11, 2026). Who Counts? Single-Center Audit Probes Whether a National Psoriasis Registry Truly Reflects Real Patients. Scienmag.
